Edition:
United Kingdom

TapImmune Inc (TPIV.OQ)

TPIV.OQ on NASDAQ Stock Exchange Capital Market

3.28USD
2:43pm GMT
Change (% chg)

$0.08 (+2.50%)
Prev Close
$3.20
Open
$3.26
Day's High
$3.28
Day's Low
$3.26
Volume
1,400
Avg. Vol
4,704
52-wk High
$5.35
52-wk Low
$2.62

Latest Key Developments (Source: Significant Developments)

Tapimmune Announces Enrollment Of First Patient In Phase 2 Clinical Trial For Treating Triple-Negative Breast Cancer
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Tapimmune Inc ::TAPIMMUNE ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PHASE 2 CLINICAL TRIAL FOR TREATING TRIPLE-NEGATIVE BREAST CANCER FUNDED BY U.S. DEPARTMENT OF DEFENSE.TAPIMMUNE INC - 280-PATIENT PHASE 2 TRIAL, SPONSORED BY MAYO CLINIC, RECEIVED $13.3 MILLION IN GRANT FUNDING FROM U.S. DEPARTMENT OF DEFENSE.TAPIMMUNE - ‍INTERIM IMMUNOGENICITY RESULTS FROM ONGOING STUDY EVALUATING TPIV200 IN RANDOMIZED DOSING TRIAL IN TNBC ANTICIPATED IN FIRST HALF OF 2018.  Full Article

Tapimmune Q3 loss earnings per share $0.39‍​
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Tapimmune Inc :Tapimmune provides third quarter 2017 corporate and clinical update.Tapimmune Inc - qtrly loss earnings per share $0.39‍​.  Full Article

TapImmune says 280-patient efficacy trial sponsored by Mayo Clinic evaluating TPIV200 efficacy expected to begin by year end 2017​
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - TapImmune Inc ::TapImmune Inc - 280-patient efficacy trial sponsored by Mayo Clinic evaluating TPIV200 efficacy expected to begin by year end 2017​.TapImmune - ‍enrolled final patient in randomized Phase 2 clinical study of novel T-cell vaccine candidate TPIV200.TapImmune Inc - ‍look forward to reporting interim immunogenicity results in first half of 2018 from TPIV200 study​.  Full Article

Tapimmune advances TPIV 200 phase 2 triple-negative breast cancer trial
Wednesday, 15 Feb 2017 

Tapimmune Inc : Tapimmune advances TPIV 200 phase 2 triple-negative breast cancer trial after favorable DSMB safety review . Tapimmune Inc - will be enrolling remaining patients in trial at 12 clinical centers in U.S. with enrollment completion targeted for end of 2017 .Tapimmune Inc- have two additional phase 2 trials now enrolling or about to enroll ovarian and triple-negative breast cancer patients.  Full Article

No consensus analysis data available.